Novo Nordisk, the corporate behind Ozempic and Wegovy, revealed a brand new evaluation of the longest research it has performed thus far by the lens of long-term weight reduction.
The 17,604-person research, revealed in Nature Medication and introduced on the European Congress on Weight problems in Venice, Italy on Tuesday, confirmed for the primary time that weight problems sufferers with out diabetes maintained a ten% common weight reduction over 4 years after taking Wegovy.
“We see that after the vast majority of the burden loss is accrued, you do not return and begin to enhance in weight for those who keep on the drug,” Martin Holst Lange, Novo’s improvement head, informed Reuters in an interview.
The findings present that Wegovy is efficient in the long run, over a number of years, supplied sufferers keep on it.
Associated: Novo Nordisk Is Value Extra Than Denmark’s GDP Because of America’s Ozempic and Wegovy Craze
An extra evaluation launched Tuesday based mostly on the identical information confirmed that Wegovy had advantages for the guts, no matter how a lot weight research contributors misplaced whereas taking it.
Wegovy diminished the chance of stroke by 20% in chubby or overweight folks with a historical past of coronary heart illness.
Researchers do not exactly understand how Wegovy’s energetic ingredient, semaglutide, protects the guts, and are conducting research to know it.
“We now additionally perceive that whereas we all know that physique weight reduction is necessary, it isn’t the one factor driving the cardiovascular good thing about semaglutide remedy,” Lange informed Reuters on Tuesday.
Associated: These U.S. Well being Insurers Will Now Cowl Wegovy, the Wildly Well-liked $1,349 Weight-Loss Drug
The information may add to Novo’s case to have its weight reduction medication be extra broadly lined by insurance coverage firms in international locations just like the U.S. and the U.Ok.
Nonetheless, there have been downsides to taking Wegovy recorded within the report — about 17% of those that took the drug left the research early due to stomach-related points like nausea.
Novo has made Wegovy out there in 10 international locations thus far, together with the U.S., Norway, Japan, and Spain, since releasing the drug in 2021. Costs begin at $200 and may attain nearly $2,000 monthly, relying on the nation.
Within the U.S., Ozempic goes for about $936 a month out of pocket whereas Wegovy sells for about $1,350 a month.
Costco created a program in April that provides members direct entry to Ozempic and Wegovy when acceptable, although the treatment price falls straight on clients or medical health insurance.
Associated: Costco Declares Ozempic, Wegovy Prescriptions and New Weight Loss Program
Novo mentioned earlier this month that a minimum of 25,000 folks within the U.S. begin Wegovy per week.
